Eli Lilly Apr 28, 2026 Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ - BioSpace
Eli Lilly Apr 28, 2026 Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing - Fierce Biotech
Eli Lilly Apr 28, 2026 Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine - Business Wire
Eli Lilly Apr 27, 2026 Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs - CNBC
Eli Lilly Apr 27, 2026 Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet - Reuters
Eli Lilly Apr 27, 2026 Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax - Fierce Biotech
FierceBiotech Apr 24, 2026 After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
BioPharma Dive Apr 24, 2026 Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
FierceBiotech Apr 22, 2026 Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Insilico Medicine Apr 21, 2026 Insilico Medicine and Eli Lilly and Company Partner on AI-Driven Drug Discovery - CDO Magazine
BioPharma Dive Apr 17, 2026 Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool